Research Paper Volume 16, Issue 21 pp 13392—13408
Pan-cancer analysis identifies the oncogenic role of CCNE1 in human cancers
- 1 Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China
- 2 Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- 3 Department of Orthopedic Surgery, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Ürümqi 830054, China
- 4 Department of Orthopedics, Changsha Hospital, Xiangya Medical College, Central South University, Changsha 410005, China
- 5 Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
Received: March 9, 2024 Accepted: November 11, 2024 Published: November 25, 2024
https://doi.org/10.18632/aging.206163How to Cite
Copyright: © 2024 Ouyang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective: To investigate expression, prognosis, immune cell infiltration of Cyclin E1 (CCNE1) in cancer.
Methods: We used TIMER and GEPIA datasets to analyze the differential expression of CCNE1 in multiple tumors. GEPIA and Kaplan-Meier plotter databases were utilized to observe the prognostic significance of CCNE1 in cancer. TIMER and cBioPortal databases were adopted for the analysis regarding immune infiltration and mutation respectively.
Results: The results showed that CCNE1 was highly expressed in multiple cancers including BLCA, BRCA, CHOL, COAD, ESCA, HNSC, KICH, KIRC, KIRP, LIHC, LUAD, LUSC, READ, STAD, THCA, UCEC (P < 0.001) and CESC (P < 0.01). High CCNE1 expression was associated with a poor overall survival prognosis in several cancers, including ACC, BRCA, KIRC, KIRP, LGG, LIHC, LUAD and MESO. Additionally, CCNE1 expression was correlated with the cancer-associated immune infiltration level in BRCA, COAD, LUSC, STAD and THYM.
Conclusions: CCNE1 is expected to be a potential biomarker for tumor prognosis and immune infiltration in various cancers.
Abbreviations
ACC: Adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; COAD: Colon adenocarcinoma; READ: Rectum adenocarcinoma Esophageal carcinoma; DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HCC: Hepatocelluar carcinoma; HNSC: Head and Neck squamous cell carcinoma; KICH: Kidney Chromophobe; KIPAN: Pan-kidney cohort (KICH+KIRC+KIRP); KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute Myeloid Leukemia; LGG: Brain Lower Grade Glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin Cutaneous Melanoma; STAD: Stomach adenocarcinoma; STES: Stomach and Esophageal carcinoma; TGCT: Testicular Germ Cell Tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine Corpus Endometrial Carcinoma; UCS: Uterine Carcinosarcoma; UVM: Uveal Melanoma.